AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00596947
Drug: rabbit antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
Trial: NCT02738190
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin 5% added to blood priming solution
Trial: NCT00184600
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
Trial: NCT00184600
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
Trial: NCT00184600
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
Trial: NCT03726788
Drug: Botulinum Toxin Type A 100U
RxNorm normalized name: BOTULINUM TOXIN TYPE A 100UNT/VIL OPH
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
Trial: NCT03726788
Drug: Botulinum Toxin Type A 200U
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
Trial: NCT03726788
Drug: Triamcinolone Hexacetonide Inj Susp 20 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one intra-articular injection of 2 ml Triamcinolone Hexacetonide
Trial: NCT00707161
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
Trial: NCT00278980
Drug: C-peptide
RxNorm normalized name: C-peptide
DrugBank: C-peptide (DB16187)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00882180
Drug: ALN-VSP02
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion administered every two weeks
Trial: NCT01237522
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose study with one tablet of metformin 500 mg, time frame 24 hours
Trial: NCT00596947
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
Trial: NCT00596947
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
Trial: NCT00596947
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
Trial: NCT00596947
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
Trial: NCT02700412
Drug: Epidiolex
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Trial: NCT01541189
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
Trial: NCT02486653
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
Trial: NCT00612170
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral tablet once a day dosing
Trial: NCT00612170
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg oral tablet once a day dosing
Trial: NCT00612170
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg oral tablet once a day dosing
Trial: NCT00621153
Drug: Candesartan Cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan Cilexetil 16 mg oral
Trial: NCT00621153
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg
Trial: NCT00621153
Drug: Candesartan Cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan Cilexetil 32 mg oral
Trial: NCT00864981
Drug: Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01568775
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patient and subjects received single dose of aliskiren 300 mg in treatment period.
Trial: NCT01386593
Drug: Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01386593
Drug: Basel cocktail + Rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00535054
Drug: Tears Again
RxNorm normalized name: Tears Again
DrugBank: Polyvinyl alcohol (DB11060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposome Eye Spray
Trial: NCT00715377
Drug: Benztropine
RxNorm normalized name: Benztropine
DrugBank: Benzatropine (DB00245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
Trial: NCT04623541
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
Trial: NCT04623541
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
Trial: NCT04623541
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
Trial: NCT03109977
Drug: Zr-DFO-pertuzumab PET/CT
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
Trial: NCT01726205
Drug: Pregabalin and normal saline infusion, PRG
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01726205
Drug: Pregabalin and ropivacaine 02% infusion
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04517162
Drug: Collagen-Polyvinylpyrrolidone
RxNorm normalized name: Collagen-polyvinylpyrrolidone
DrugBank: Collagen-polyvinylpyrrolidone (DB16525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL of polymerized-type I collagen or placebo, every 12 h for 3 days and then every 24 h for 4 days (in total 10 injections in 7 days)
Trial: NCT00492960
Drug: larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsules
Trial: NCT01530620
Drug: Propiverine hydrochloride ER (extended release)
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg capsule (1x1/d)
Trial: NCT01530620
Drug: Propiverine hydrochloride IR (immediate release)
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg tablet (3x1/d)
Trial: NCT00003674
Drug: dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01364194
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
Trial: NCT00301366
Drug: alpha-1 proteinase inhibitor (human)
RxNorm normalized name: Alpha-1 proteinase inhibitor (human)
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg weekly for 20 weeks
Trial: NCT01911520
Drug: Sugammadex 2 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive 2 mg/kg Sugammadex.
Trial: NCT01911520
Drug: Sugammadex. 4 mg/kg
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive 4 mg/kg Sugammadex.
Trial: NCT04623541
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib tablets will be administered in cycles of 28 days for a total of 24 cycles.
Trial: NCT04340557
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
Trial: NCT01054586
Drug: Intervention D
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 g TOPICAL CREAM [AGE INTERVENTION DUALITY]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
Trial: NCT01054586
Drug: Intervention E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
Trial: NCT00886275
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
Trial: NCT00886275
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
Trial: NCT00886275
Drug: Dexmedetomidine, Midazolam
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
Trial: NCT02841033
Drug: daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
Trial: NCT01496183
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
Trial: NCT01434147
Drug: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
Trial: NCT04459585
Drug: Dabigatran Etexilate Mesylate
RxNorm normalized name: Dabigatran Etexilate Mesylate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral 150 mg capsule dose
Trial: NCT04459585
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
Trial: NCT01723748
Drug: genotropin
RxNorm normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
Trial: NCT01061866
Drug: 3-phthalimidoglutarimide (Thalidomide)
RxNorm normalized name: 3-Phthalimidoglutarimide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at 200 mg dosage bid was administered during a twelve month period.
Trial: NCT00904345
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
Trial: NCT00042900
Drug: pyroxamide
RxNorm normalized name: Pyroxamide
DrugBank: Pyroxamide (DB12847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02939430
Drug: Sugammadex intravenous
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
Trial: NCT02939430
Drug: Intravenous neostigmine and atropine
RxNorm normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00702195
Drug: Org 36286 (corifollitropin alfa)
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
Trial: NCT02409290
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
Trial: NCT02409290
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
Trial: NCT02409290
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
Trial: NCT02409290
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
Trial: NCT02409290
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
Trial: NCT02409290
Drug: Prothionamide
RxNorm normalized name: prothionamide
DrugBank: Protionamide (DB12667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothionamide has a bacteriostatic action.
Trial: NCT02409290
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
Trial: NCT02409290
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
Trial: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Quinine pills
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)
Trial: NCT04553705
Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg
Trial: NCT04553705
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol care of COVID-19 infection
Trial: NCT00332254
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg IL1Ra ia x1 vs saline ia x1
Trial: NCT04206605
Drug: Lanadelumab
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lanadelumab solution in a PFS for injection.